China Rosuvastatin Market Report 2018: Analysis 2013-2017 & Forecasts 2018-2022

DUBLIN, Dec 4, 2018 /PRNewswire/ --

The "Investigation Report on China's Rosuvastatin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of AstraZeneca's branded Rosuvastatin is Crestor.

After Rosuvastatin was launched, its sales value grew sharply. Rosuvastatin has become a key product of statins. In 2012, Rosuvastatin became the number one lipid-lowering drug in the world with a sales value of USD 6.2 billion.

With the improvement of living standards and the change in diet, from 1978 to 2018, Chinese people's blood lipid levels kept rising, and the incidence of dyslipidemia increased significantly. The overall incidence of dyslipidemia in Chinese adults is up to about 40%. As dyslipidemia is a major cause of the development of coronary heart disease, strokes and other atherosclerotic lesions, active treatment of hyperlipidemia can reduce the incidence of these diseases.

In China, Rosuvastatin is used to treat primary hypercholesterolemia (Type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (Type IIb) that cannot be properly controlled via diet control and non-drug treatments (e.g. sports therapy and weight loss). In the treatment of homozygous familial hypercholesterolemia, it complements the diet control and other lipid-lowering measures (such as LDL removal), or serves as an alternative when these measures do not work.

According to the author, Rosuvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 2 million in 2007 to more than CNY 1.1 billion in 2017. At present, China's Rosuvastatin market is dominated by IPR PHARMACEUTICALS INC. (ASTRAZENECA), Lunan Better Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., etc. Pfizer has the largest market share by sales value which was about 67% in 2017.

It is expected that as more Chinese people suffer from hyperlipidemia, China's Rosuvastatin market will continue to grow in the next few years.

Topics Covered:

• Situation of hyperlipidemia in China
• Market size of Rosuvastatin in China
• Competitive landscape of China's Rosuvastatin market
• Prices of Rosuvastatin in China
• Prospect of China's Rosuvastatin market from 2018 to 2022

Key Topics Covered:

1 Relevant Concepts of Rosuvastatin
1.1 Indications for Rosuvastatin
1.2 Development of Rosuvastatin in China
1.3 Patents and Government Approval on Rosuvastatin in China

2 Sales of Rosuvastatin in China, 2013-2017
2.1 Sales Value of Rosuvastatin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Rosuvastatin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Rosuvastatin by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules

3 Analysis on Major Rosuvastatin Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Rosuvastatin Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 IPR Pharmaceuticals Inc.(Astrazeneca)
3.2.1 Enterprise Profile
3.2.2 Sales of Rosuvastatin by IPR Pharmaceuticals Inc.(Astrazeneca) in China
3.3 Lunan Better Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Rosuvastatin by Lunan Better Pharmaceutical Co., Ltd. in China
3.4 Zhejiang Jingxin Pharmaceutical Co., Ltd.
3.5 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
3.6 Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.

4 Prices of Rosuvastatin in China, 2017-2018
4.1 IPR Pharmaceuticals Inc.(Astrazeneca)(Crestor)
4.2 Lunan Better Pharmaceutical Co., Ltd. (Ruizhi)
4.3 Zhejiang Jingxin Pharmaceutical Co., Ltd. (Jingnuo)
4.4 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (Tuotuo)
4.5 Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd. (Shufutan)

5 Prospect of China's Rosuvastatin Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/research/gpmdxs/china?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com